Obstetrics, Gynecology and Reproductive Biology Research
Symptomatic Endometriosis Study
This study is currently closed to enrollment.
Assess efficacy and safety of three different doses of P2X3 antagonist in women with symptomatic endometriosis
AGE: 18 years and over
GENDER: Female
GENDER: Female
TYPE: Drug Study
CONDITION: Premenopausal, Endometriosis
HEALTHY PARTICIPANTS: No
CONDITION: Premenopausal, Endometriosis
HEALTHY PARTICIPANTS: No
DEPARTMENT: Obstetrics & Gynecology
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Study Purpose
The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis.
Who Can Participate
Women between 18 and 49 years of age who are premenopausal and are diagnosed with moderate to severe endometriosis may be eligible for this study.